TUSTIN, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for the treatment of hepatitis C infection (HCV) and cancer, today announced financial results for the first quarter of fiscal year 2007 ended July 31, 2006. The company reported a consolidated net loss of $5,457,000, or $0.03 per basic and diluted share, compared to a consolidated net loss of $4,339,000 or $0.03 per basic and diluted share for the same prior year period.
